0	0	1999-09-21	CD	O	O	B-Num
0	1	01	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	54	CD	O	O	I-Num
0	4	MINIMED	NNP	O	O	B-Org
0	5	INSULIN	NNP	O	O	I-Org
0	6	PUMP	NNP	O	O	I-Org
0	7	PROSPECTS	NNS	O	O	O
0	8	BOOST	NNP	O	O	O
0	9	STOCK	NN	O	O	O

1	0	LOS	NNP	O	O	B-Loc
1	1	ANGELES	NNP	O	O	I-Loc
1	2	_	NN	O	O	O
1	3	As	IN	O	O	O
1	4	one	CD	O	B-NP	B-Num
1	5	of	IN	O	B-PP	O
1	6	its	PP$	O	B-NP	O
1	7	main	JJ	O	I-NP	O
1	8	products	NNS	O	I-NP	O
1	9	nears	VBZ	O	B-VP	O
1	10	approval	NN	O	B-NP	O
1	11	by	IN	O	B-PP	O
1	12	the	DT	O	B-NP	O
1	13	federal	JJ	O	I-NP	O
1	14	government	NN	O	I-NP	O
1	15	's	POS	O	B-NP	O
1	16	Medicare	NNP	O	I-NP	O
1	17	reimbursement	NN	O	I-NP	O
1	18	arm	NN	O	I-NP	O
1	19	COMMA	COMMA	O	O	O
1	20	MiniMed	NNP	O	B-NP	B-Peop
1	21	's	POS	O	B-NP	O
1	22	stock	NN	O	I-NP	O
1	23	has	VBZ	O	B-VP	O
1	24	been	VBN	O	I-VP	O
1	25	flirting	VBG	O	I-VP	O
1	26	with	IN	O	B-PP	O
1	27	record	JJ	O	B-NP	O
1	28	high	JJ	O	I-NP	O
1	29	prices	NNS	O	I-NP	O
1	30	.	.	O	O	O

2	0	Shares	NNS	O	B-NP	O
2	1	of	IN	O	B-PP	O
2	2	the	DT	O	B-NP	O
2	3	Los	NNP	O	I-NP	O
2	4	Angeles-based	JJ	O	I-NP	B-OrgCorp
2	5	medical	JJ	O	I-NP	O
2	6	products	NNS	O	I-NP	O
2	7	company	NN	O	I-NP	B-OrgCorp
2	8	closed	VBD	O	B-VP	O
2	9	Monday	NNP	O	B-NP	B-Date
2	10	at	IN	O	B-PP	O
2	11	$101	NN	O	B-NP	B-Money
2	12	COMMA	COMMA	O	O	O
2	13	up	IN	O	O	O
2	14	$3.6875	NN	O	B-NP	B-Money
2	15	for	IN	O	B-PP	O
2	16	the	DT	O	B-NP	O
2	17	day	NN	O	I-NP	B-DayFest
2	18	and	CC	O	O	O
2	19	just	RB	O	B-VP	O
2	20	shy	VBP	O	I-VP	O
2	21	of	IN	O	B-PP	O
2	22	last	JJ	O	B-NP	O
2	23	week	NN	O	I-NP	O
2	24	's	POS	O	B-NP	O
2	25	52-week	JJ	O	I-NP	B-Num
2	26	high	JJ	O	I-NP	O
2	27	of	IN	O	B-PP	O
2	28	$102.875	NN	O	B-NP	B-Money
2	29	.	.	O	O	O

3	0	The	DT	O	B-NP	O
3	1	company	NN	O	I-NP	B-OrgCorp
3	2	is	VBZ	O	B-VP	O
3	3	awaiting	VBG	O	I-VP	O
3	4	approval	NN	O	B-NP	O
3	5	for	IN	O	B-PP	O
3	6	its	PP$	O	B-NP	O
3	7	external	JJ	O	I-NP	O
3	8	insulin	NN	O	I-NP	O
3	9	pump	NN	O	I-NP	O
3	10	by	IN	O	B-PP	O
3	11	the	DT	O	B-NP	O
3	12	Health	NNP	O	I-NP	B-OrgPolBody
3	13	Care	NNP	O	I-NP	I-OrgPolBody
3	14	Financing	NNP	O	I-NP	I-OrgPolBody
3	15	Administration	NNP	O	I-NP	I-OrgPolBody
3	16	COMMA	COMMA	O	O	O
3	17	the	DT	O	B-NP	O
3	18	agency	NN	O	I-NP	B-OrgCorp
3	19	that	WDT	O	B-NP	O
3	20	decides	VBZ	O	B-VP	O
3	21	whether	IN	O	O	O
3	22	Medicare	NNP	O	B-NP	B-Peop
3	23	will	MD	O	B-VP	O
3	24	reimburse	VB	O	I-VP	O
3	25	patients	NNS	O	B-NP	O
3	26	for	IN	O	B-PP	O
3	27	treatments	NNS	O	B-NP	O
3	28	.	.	O	O	O

4	0	The	DT	O	B-NP	O
4	1	approval	NN	O	I-NP	O
4	2	is	VBZ	O	B-VP	O
4	3	``	``	O	O	O
4	4	highly	RB	O	O	O
4	5	probableCOMMA	NN	O	O	O
4	6	''	''	O	O	O
4	7	said	VBD	O	B-VP	O
4	8	Kurt	NNP	O	B-NP	B-Peop
4	9	Kruger	NNP	O	I-NP	I-Peop
4	10	COMMA	COMMA	O	O	O
4	11	an	DT	O	B-NP	O
4	12	analyst	NN	O	I-NP	B-ProfTitle
4	13	with	IN	O	B-PP	O
4	14	Banc	NNP	O	O	O
4	15	of	IN	O	B-PP	O
4	16	America	NNP	O	B-NP	B-Loc
4	17	Securities	NNPS	O	I-NP	O
4	18	in	IN	O	B-PP	O
4	19	San	NNP	O	B-NP	B-LocCit
4	20	Francisco	NNP	O	I-NP	I-LocCit
4	21	.	.	O	O	O

5	0	If	IN	O	O	O
5	1	the	DT	O	B-NP	O
5	2	federal	JJ	O	I-NP	O
5	3	government	NN	O	I-NP	O
5	4	decides	VBZ	O	B-VP	O
5	5	the	DT	O	B-NP	O
5	6	product	NN	O	I-NP	O
5	7	is	VBZ	O	B-VP	O
5	8	worth	JJ	O	O	O
5	9	reimbursing	VBG	O	O	O
5	10	its	PP$	O	B-NP	O
5	11	patients	NNS	O	I-NP	O
5	12	COMMA	COMMA	O	O	O
5	13	the	DT	O	B-NP	O
5	14	pressure	NN	O	I-NP	O
5	15	will	MD	O	B-VP	O
5	16	be	VB	O	I-VP	O
5	17	on	IN	O	B-PP	O
5	18	private	JJ	O	B-NP	O
5	19	insurers	NNS	O	I-NP	O
5	20	and	CC	O	O	O
5	21	HMOs	NNP	O	B-NP	B-Org
5	22	to	TO	O	B-VP	O
5	23	follow	VB	O	I-VP	O
5	24	suit	NN	O	B-NP	O
5	25	COMMA	COMMA	O	O	O
5	26	Kruger	NNP	O	B-NP	B-Peop
5	27	said	VBD	O	B-VP	O
5	28	.	.	O	O	O

6	0	And	CC	O	O	O
6	1	all	DT	O	B-NP	O
6	2	of	IN	O	B-PP	O
6	3	these	DT	O	B-NP	O
6	4	approvals	NNS	O	I-NP	O
6	5	probably	RB	O	O	O
6	6	would	MD	O	B-VP	O
6	7	mean	VB	O	I-VP	O
6	8	increased	VBN	O	B-NP	O
6	9	sales	NNS	O	I-NP	O
6	10	and	CC	O	I-NP	O
6	11	profits	NNS	O	I-NP	O
6	12	for	IN	O	B-PP	O
6	13	MiniMed	NNP	O	B-NP	O
6	14	COMMA	COMMA	O	O	O
6	15	he	PRP	O	B-NP	O
6	16	said	VBD	O	B-VP	O
6	17	.	.	O	O	O

7	0	It	PRP	O	B-NP	O
7	1	's	VBZ	O	B-VP	O
7	2	unknown	NN	O	B-NP	O
7	3	COMMA	COMMA	O	O	O
7	4	however	RB	O	O	O
7	5	COMMA	COMMA	O	O	O
7	6	how	WRB	O	O	O
7	7	much	JJ	O	O	O
7	8	sales	NNS	O	B-NP	O
7	9	would	MD	O	B-VP	O
7	10	increase	VB	O	I-VP	O
7	11	with	IN	O	B-PP	O
7	12	HCFA	NNP	O	B-NP	O
7	13	and	CC	O	I-NP	O
7	14	HMO	NNP	O	I-NP	B-Org
7	15	adoptions	NNS	O	I-NP	O
7	16	;	:	O	O	O
7	17	company	NN	O	B-NP	B-OrgCorp
7	18	officials	NNS	O	I-NP	O
7	19	were	VBD	O	B-VP	O
7	20	unavailable	JJ	O	O	O
7	21	for	IN	O	B-PP	O
7	22	comment	NN	O	B-NP	O
7	23	Monday	NNP	O	B-NP	B-Date
7	24	afternoon	NN	O	I-NP	O
7	25	.	.	O	O	O

8	0	Patients	NNS	O	B-NP	O
8	1	wear	VBP	O	B-VP	O
8	2	MiniMed	NNP	O	B-NP	B-Peop
8	3	's	POS	O	B-NP	O
8	4	insulin	NN	O	I-NP	O
8	5	pump	NN	O	I-NP	O
8	6	on	IN	O	B-PP	O
8	7	a	DT	O	B-NP	O
8	8	belt	NN	O	I-NP	O
8	9	.	.	O	O	O

9	0	It	PRP	O	B-NP	O
9	1	delivers	VBZ	O	B-VP	O
9	2	a	DT	O	B-NP	O
9	3	constant	JJ	O	I-NP	O
9	4	dose	NN	O	I-NP	B-Medical
9	5	of	IN	O	B-PP	O
9	6	insulin	NN	O	B-NP	O
9	7	through	IN	O	B-PP	O
9	8	a	DT	O	B-NP	O
9	9	tube	NN	O	I-NP	O
9	10	in	IN	O	B-PP	O
9	11	the	DT	O	B-NP	O
9	12	abdomen	NNS	O	I-NP	B-Medical
9	13	COMMA	COMMA	O	O	O
9	14	thus	RB	O	O	O
9	15	eliminating	VBG	O	B-VP	O
9	16	the	DT	O	B-NP	O
9	17	need	NN	O	I-NP	O
9	18	for	IN	O	B-PP	O
9	19	repeated	VBN	O	B-NP	O
9	20	injections	NNS	O	I-NP	O
9	21	during	IN	O	B-PP	O
9	22	the	DT	O	B-NP	O
9	23	day	NN	O	I-NP	B-DayFest
9	24	and	CC	O	O	O
9	25	allowing	VBG	O	B-VP	O
9	26	patients	NNS	O	B-NP	O
9	27	to	TO	O	B-VP	O
9	28	control	VB	O	I-VP	O
9	29	their	PP$	O	B-NP	O
9	30	dosage	NN	O	I-NP	B-Medical
9	31	of	IN	O	B-PP	O
9	32	insulin	NN	O	B-NP	O
9	33	.	.	O	O	O

10	0	Kruger	NNP	O	B-NP	B-Peop
10	1	COMMA	COMMA	O	O	O
10	2	who	WP	O	B-NP	O
10	3	recommends	VBZ	O	B-VP	O
10	4	the	DT	O	B-NP	O
10	5	stock	NN	O	I-NP	O
10	6	as	IN	O	B-PP	O
10	7	a	DT	O	B-NP	O
10	8	strong	JJ	O	I-NP	O
10	9	buy	NN	O	I-NP	O
10	10	COMMA	COMMA	O	O	O
10	11	said	VBD	O	B-VP	O
10	12	the	DT	O	B-NP	O
10	13	stock	NN	O	I-NP	O
10	14	price	NN	O	I-NP	O
10	15	isn	NN	O	I-NP	O
10	16	't	NN	O	I-NP	O
10	17	done	VBN	O	B-VP	O
10	18	climbing	VBG	O	I-VP	O
10	19	.	.	O	O	O

11	0	``	``	O	O	O
11	1	The	DT	O	B-NP	O
11	2	potential	NN	O	I-NP	O
11	3	and	CC	O	O	O
11	4	the	DT	O	B-NP	O
11	5	prospects	NNS	O	I-NP	O
11	6	that	IN	O	O	O
11	7	this	DT	O	B-NP	O
11	8	company	NN	O	I-NP	B-OrgCorp
11	9	possesses	VBZ	O	B-VP	O
11	10	are	VBP	O	B-VP	O
11	11	just	RB	O	I-VP	O
11	12	now	RB	O	I-VP	O
11	13	being	VBG	O	I-VP	O
11	14	realized	VBN	O	I-VP	O
11	15	and	CC	O	O	O
11	16	appreciated	VBD	O	B-VP	O
11	17	by	IN	O	B-PP	O
11	18	Wall	NNP	O	B-NP	O
11	19	StreetCOMMA	NNP	O	I-NP	O
11	20	''	''	O	I-NP	O
11	21	Kruger	NNP	O	I-NP	B-Peop
11	22	said	VBD	O	B-VP	O
11	23	.	.	O	O	O

12	0	``	``	O	O	O
12	1	They	PRP	O	B-NP	O
12	2	could	MD	O	B-VP	O
12	3	have	VB	O	I-VP	O
12	4	margins	NNS	O	B-NP	O
12	5	that	WDT	O	B-NP	O
12	6	are	VBP	O	B-VP	O
12	7	about	IN	O	B-NP	O
12	8	twice	RB	O	I-NP	O
12	9	the	DT	O	I-NP	O
12	10	level	NN	O	I-NP	O
12	11	they	PRP	O	B-NP	O
12	12	are	VBP	O	B-VP	O
12	13	now	RB	O	O	O
12	14	.	.	O	O	O
12	15	''	''	O	O	O

13	0	MiniMed	NNP	O	B-NP	O
13	1	controls	NNS	O	I-NP	O
13	2	about	IN	O	O	O
13	3	85	CD	O	B-NP	B-NumPercent
13	4	percent	NN	O	I-NP	I-NumPercent
13	5	of	IN	O	B-PP	O
13	6	the	DT	O	B-NP	O
13	7	U.S.	NNP	O	I-NP	B-LocCoun
13	8	market	NN	O	I-NP	O
13	9	and	CC	O	O	O
13	10	35	CD	O	B-NP	B-NumPercent
13	11	percent	NN	O	I-NP	I-NumPercent
13	12	of	IN	O	B-PP	O
13	13	the	DT	O	B-NP	O
13	14	European	JJ	O	I-NP	B-LangRace
13	15	market	NN	O	I-NP	O
13	16	for	IN	O	B-PP	O
13	17	external	JJ	O	B-NP	O
13	18	insulin	NN	O	I-NP	O
13	19	pumps	NNS	O	I-NP	O
13	20	and	CC	O	O	O
13	21	has	VBZ	O	B-VP	O
13	22	only	RB	O	B-NP	O
13	23	one	CD	O	I-NP	B-Num
13	24	competitor	NN	O	I-NP	O
13	25	COMMA	COMMA	O	O	O
13	26	Disetronic	NNP	O	B-NP	O
13	27	Holding	NNP	O	I-NP	B-Peop
13	28	AG	NNP	O	I-NP	I-Peop
13	29	.	.	O	O	O

14	0	``	``	O	O	O
14	1	MiniMed	NNP	O	B-NP	B-Peop
14	2	is	VBZ	O	B-VP	O
14	3	the	DT	O	B-NP	O
14	4	hands-down	JJ	O	I-NP	O
14	5	leader	NN	O	I-NP	B-ProfTitle
14	6	and	CC	O	O	O
14	7	essentially	RB	O	B-NP	O
14	8	the	DT	O	I-NP	O
14	9	only	JJ	O	I-NP	O
14	10	company	NN	O	I-NP	B-OrgCorp
14	11	in	IN	O	B-PP	O
14	12	the	DT	O	B-NP	O
14	13	marketCOMMA	NN	O	I-NP	O
14	14	''	''	O	O	O
14	15	Kruger	NNP	O	B-NP	B-Peop
14	16	said	VBD	O	B-VP	O
14	17	.	.	O	O	O

15	0	``	``	O	O	O
15	1	They	PRP	O	B-NP	O
15	2	owe	VBP	O	B-VP	O
15	3	that	DT	O	B-NP	O
15	4	market	NN	O	I-NP	O
15	5	share	NN	O	I-NP	O
15	6	and	CC	O	O	O
15	7	that	DT	O	B-NP	O
15	8	lead	VBP	O	B-VP	O
15	9	position	NN	O	B-NP	O
15	10	to	TO	O	B-PP	O
15	11	their	PP$	O	B-NP	O
15	12	superior	JJ	O	I-NP	O
15	13	technology	NN	O	I-NP	O
15	14	COMMA	COMMA	O	O	O
15	15	and	CC	O	O	O
15	16	more	RBR	O	O	O
15	17	importantly	RB	O	O	O
15	18	to	TO	O	B-PP	O
15	19	their	PP$	O	O	O
15	20	extensive	JJ	O	B-NP	O
15	21	marketing	NN	O	I-NP	O
15	22	and	CC	O	I-NP	O
15	23	distribution	NN	O	I-NP	O
15	24	efforts	NNS	O	I-NP	O
15	25	COMMA	COMMA	O	O	O
15	26	which	WDT	O	B-NP	O
15	27	have	VBP	O	B-VP	O
15	28	built	VBN	O	I-VP	O
15	29	this	DT	O	B-NP	O
15	30	franchise	NN	O	I-NP	O
15	31	for	IN	O	B-PP	O
15	32	them	PRP	O	B-NP	O
15	33	.	.	O	O	O
15	34	''	''	O	O	O
